Mylan Pharmaceuticals hopes its $107 million verdict against GlaxoSmithKline is just the first of a two-part victory in preserving its rights to market generic Paxil.
March 28, 2014 at 06:27 PM
1 minute read
Mylan Pharmaceuticals hopes its $107 million verdict last week against GlaxoSmithKline is just the first of a two-part victory in preserving its rights to market generic Paxil.
A federal court jury in Trenton found Glaxo’s 2010 deal with a Canadian drug maker, Apotex, breached its 2007 contract giving Mylan rights to sell its version of the antidepressant.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
